EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model

William A Murphy iD, Noora Sjöstedt iD, Mailys De Sousa Mendes iD, Mattie Hartauer iD, Kim L R Brouwer iD, Sibylle Neuhoff iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-01 · 15 (1)

DOI: 10.1002/psp4.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 13.11.2025. Verfasst von William A Murphy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill,…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Models, Biological, Obesity, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Statins are frequently prescribed for hyperlipidemia, a common comorbidity in patients with obesity and/or metabolic dysfunction‐associated steatohepatitis (MASH). However, limited knowledge exists on how MASH may alter statin disposition within hepatocytes where the statin target, 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, is located. This study used a physiologically based pharmacokinetic (PBPK)/permeability‐limited multicompartment liver (PerMCL) framework, incorporating zonal transporter and drug‐metabolizing enzyme data. Systemic and hepatocellular concentrations of pravastatin, rosuvastatin, and atorvastatin were simulated in Healthy Volunteers (HV), Obese, Morbidly Obese, and MASH virtual populations with the Simcyp Simulator. A pharmacodynamic model in Simcyp Designer was then used to simulate alterations in rosuvastatin cholesterol‐lowering efficacy between these populations. Hepatic transport and metabolism pathways were verified against clinical data. Organic anion transporting polypeptide (OATP)1B model uptake pathways were verified using genotype and drug–drug interaction data. Atorvastatin metabolism pathways were verified using metabolite data. Steady‐state plasma and zonal hepatocellular concentration–time profiles for each statin were simulated across virtual populations of 100 individuals aged 40–65 years. Simulations predicted > 70% increases in maximal total plasma concentrations and area under the curve for pravastatin and rosuvastatin in MASH compared to HV, with changes in these parameters for atorvastatin simulated to increase > 250%. In MASH, unbound hepatocellular exposure increased by up to 127% in the periportal region for atorvastatin and decreased by up to 55% in the pericentral region for rosuvastatin. The pharmacodynamic model simulated decreased rosuvastatin cholesterol‐lowering efficacy in MASH compared with Obese, which could be compensated for with a 50% increase in dose according to exploratory simulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsModels, BiologicalObesityLiverHepatocytesNon-alcoholic Fatty Liver DiseaseHumansRosuvastatin CalciumAtorvastatinAdultPravastatinMaleComputer SimulationMiddle AgedPermeabilityFemaleDrug InteractionsLiver-Specific Organic Anion Transporter 1

Stichwörter der Autor:innen

liverpharmacokinetics‐pharmacodynamicsphysiology‐based pharmacokineticsstatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumAtorvastatinPravastatinLiver-Specific Organic Anion Transporter 1

Autor:innen und Institutionen

  • Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Certara UK Ltd., Certara Predictive Technologies, Simcyp Division, Sheffield, UK.

ORCID-Profile: William A Murphy, Noora Sjöstedt, Mailys De Sousa Mendes, Mattie Hartauer, Kim L R Brouwer, Sibylle Neuhoff

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Murphy, W. A., Sjöstedt, N., Mendes, M. S., Hartauer, M., Brouwer, K. L. R., & Neuhoff, S. (2026). Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model. CPT: Pharmacometrics & Systems Pharmacology, 15(1). https://doi.org/10.1002/psp4.70138

Vancouver

Murphy WA, Sjöstedt N, Mendes MS, Hartauer M, Brouwer KLR, Neuhoff S. Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(1). doi:10.1002/psp4.70138

BibTeX
@article{Murphy2026,
  author = {Murphy, William A and Sjöstedt, Noora and Mendes, Mailys De Sousa and Hartauer, Mattie and Brouwer, Kim L R and Neuhoff, Sibylle},
  title = {Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {1},
  doi = {10.1002/psp4.70138}
}
Kostenlos starten →